You are here

Article Text

Article menu
Download PDFPDF
Original Articles
Primary malignant mesodermal ovarian sarcomas
  1. A. Gari*,
  2. L. Souhami†,
  3. J. Arseneau‡ and
  4. G. Stanimir*
  1. *Department of Gynecology, McGill University, Montreal, Quebec, Canada
  2. †Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, Quebec, Canada
  3. ‡Department of Pathology, McGill University, Montreal, Quebec, Canada
  1. Address correspondence and reprint requests to: Luis Souhami, MD, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4. Email: luis.souhami{at}muhc.mcgill.ca

Abstract

Primary malignant mesodermal ovarian sarcomas are rare tumors and have a poor prognosis. The disease is usually diagnosed at a late stage and 5-year survivals are uncommon. Most patients are treated with debulking surgery followed by adjuvant chemotherapy. We report ten patients treated at a single institution. All patients underwent surgery and 90% received adjuvant chemotherapy. The median survival was 20 months, and only one patient survived beyond 5 years. Newer treatment strategies are urgently needed in the management of this disease.

  • malignant mixed mesodermal ovarian sarcoma
  • ovarian sarcoma

http://dx.doi.org/10.1136/ijgc-00009577-200601000-00018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.